MDMA-gestützte Therapie

ZUSAMMENFASSUNG

Neben den klassischen Psychedelika, z. B. Psilocybin, werden wieder vermehrt andere Substanzen wie 3,4-Methylendioxy-N-methylamphetamin (MDMA) erforscht. Das Entaktogen („innerlich berührend“) ist in den USA nur noch wenige Schritte von einer möglichen Zulassung zur Behandlung der posttraumatischen Belastungsstörung entfernt. Dieser Artikel soll einen Überblick über die Wirkung, den Einsatz im therapeutischen Setting sowie den Forschungsstand geben. Hierbei sollen insbesondere Sicherheitsaspekte der MDMA-gestützten Therapie beleuchtet werden. Zuletzt folgt ein Ausblick auf eine mögliche Zulassung und damit einhergehende offene Fragen, wie beispielsweise die Umsetzung in der klinischen Praxis. Auch die Notwendigkeit weiterer Studien wird diskutiert.

ABSTRACT

In addition to classic psychedelics such as Psilocybin, further substances such as 3,4-Methylendioxy-N-methylamphetamine (MDMA) are also increasingly being researched. The so-called entactogen (“to produce a touching within”) is currently close to being approved by the US American Food and Drug Administration for the treatment of post-traumatic stress disorder. This article aims to provide an overview of its effects, its use in therapeutic settings and the current state of clinical research. In particular, safety aspects of MDMA-assisted therapy are highlighted. Finally, an outlook on the imminent approval and related open questions, such as the implementation in clinical practice will follow. The need for further studies is also being discussed.

Schlüsselwörter

MDMA - PTBS - Psychedelika - MDMA-gestützte Therapie

Key words

MDMA - PTSD - psychedelics - MDMA-assisted therapy

Publikationsverlauf

Artikel online veröffentlicht:
14. Mai 2024

• Literatur

• 1 Morgan L. MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t. Ann Gen Psychiatry 2020: 19
• 2 Freudenmann RW, Öxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. Addiction 2006; 101: 1241-1245
• 3 Passie T, Benzenhöfer U. The History of MDMA as an Underground Drug in the United States, 1960–1979. J Psychoactive Drugs 2016; 48: 1-9
• 4 Mithoefer M, Wagner M, Mithoefer A. et al The Safety and Efficacy of ± 3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Chronic, Treatment-Resistant Posttraumatic Stress Disorder: The First Randomized Controlled Pilot Study. J Psychopharmacol Oxf Engl 2011; 25: 439-452
• 5 Simmler L, Rickli A, Hoener M. et al Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 2013: 79
• 6 Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev 2015; 57: 433-446
• 7 Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry 2018; 84: 221-228
• 8 Singleton SP, Wang J, Mithoefer M. et al Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. Front Psychiatry 2023; 13: 947622
• 9 Glennon RA, Yousif M, Patrick G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 1988; 29: 443-449
• 10 Baker LE, Taylor MM. Assessment of the MDA and MDMA Optical Isomers in a Stimulant-Hallucinogen Discrimination. Pharmacol Biochem Behav 1997; 57: 737-748
• 11 Mithoefer MC, Feduccia AA, Jerome L. et al MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 2019; 236: 2735-2745
• 12 Jerome L, Feduccia A, Wang J. et al Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 2020: 237
• 13 Mitchell JM, Bogenschutz M, Lilienstein A. et al MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27: 1025-1033
• 14 Mitchell JM, Ot’alora G. M, van der Kolk B. et al MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 2023; 29: 2473-2480
• 15 Wolfson PE, Andries J, Feduccia AA. et al MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep 2020; 10: 20442-20442
• 16 Danforth AL, Grob CS, Struble C. et al Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl) 2018; 235: 3137-3148
• 17 Sessa B, Higbed L, O’Brien S. et al First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol (Oxf) 2021; 35: 375-383
• 18 Brewerton TD, Wang JB, Lafrance A. et al MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res 2022; 149: 128-135
• 19 Ponte L, Jerome L, Hamilton S. et al Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. J Trauma Stress 2021: 34
• 20 Nicholas C, Wang J, Coker A. et al The Effects of MDMA-Assisted Therapy on Alcohol and Substance Use in a Phase 3 Trial for Treatment of Severe PTSD. Drug Alcohol Depend 2022; 233: 109356
• 21 Christie D, Yazar-Klosinski B, Nosova E. et al MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Front Psychiatry 2022; 13: 939302
• 22 Kvam T-M, Goksøyr I, Stewart L. et al Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”. Front Psychiatry 2022: 13